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Abstract 
Context 
The complexity of bladder cancer diagnosis and staging results in delays to definitive treatment of 
muscle-invasive bladder cancer by radical cystectomy.  
Objective 
This systematic review and meta-analyses aim to assess the impact of delays to radical cystectomy. 
Evidence Aquisition 
A systematic review was conducted by searching Medline and Ovid Gateway using protocol-driven 
search terms in August 2019 with no time limit on the studies included. The identified studies were 
assessed according to strict criteria and were assessed using the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) checklist and Risk Of Bias In Non-randomised 
Studies – of Interventions (ROBINS-I) tool. Meta-analyses were conducted based on type of delay. 
Random-effects models were used whereby the presence of a delay was the exposure variable and 
overall survival was the outcome of interest, for which pooled hazard ratios were calculated. 
Evidence Synthesis 
Nineteen studies were eligible for inclusion (17,532 patients), of which ten were included in the 
meta-analyses. A longer delay between bladder cancer diagnosis and radical cystectomy resulted in 
a pooled hazard ratio of 1.34 (95% CI: 1.18-1.53) for overall death. For delay between transurethral 
resection and cystectomy, we found a pooled hazard ratio of 1.18 (95% CI: 0.99-1.41) for overall 
death. A pooled hazard ratio of 1.04 (95%CI: 0.93-1.16) was calculated for a longer delay between 
neoadjuvant chemotherapy and radical cystectomy.  
Conclusions  
A delay in radical cystectomy after diagnosis was found to have a significantly detrimental effect on 
overall survival for bladder cancer patients. However, there was huge heterogeneity in how a delay 
was defined.  
Patient Summary 
In this review we investigated the effect of a delay in radical treatment on survival. This review 
highlights the importance of scheduling radical cystectomies in a timely manner whilst monitoring 
factors such as comorbidities and scheduling in order treat those patients requiring radical 
cystectomy without delay.  
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1.0 Introduction 
Bladder cancer (BC) is the 9th most common cancer worldwide with around 550,000 new cases in 
2018 (1). Five-year disease specific survival rates are 77% in United States of America and around 
68% in Europe (2,3). As many as 50% of MIBC patients die from metastatic disease within 3 years of 
diagnosis despite radical cystectomy (RC) (4). Delaying radical treatment is thought to contribute to 
risk of metastases and therefore decreased survival (5). Thus, for selected patients with high-risk 
non-muscle-invasive BC (NMIBC) or muscle-invasive BC (MIBC) who require RC as primary treatment, 
the European Association of Urology (EAU) recommends RC within 3 months of diagnosis (6,7). 
However, previous studies have demonstrated both increased and decreased survival associated 
with delay to RC. The impact of this delay on survival outcomes has recently been identified as one 
of the top ten unanswered research questions by BC patients and health care professionals thus 
highlighting the importance of studying this topic (8).  
 
In addition to a delay between the first symptoms and a BC diagnosis, there are several mechanisms 
by which radical definitive treatment may be delayed for BC patients (9). Patients may not be fit 
enough for immediate surgery and so require treatment of comorbidities, or may be referred from 
primary care physicians or urology units to different hospitals for surgery (10). Furthermore, seeking 
a second opinion and the need for additional investigations, particularly up to date imaging, may 
also delay RC. 
 
The most recent systematic review of the effects of delays to RC was conducted by Fahmy et al (5) in 
2006 and included 13 studies published between 1965 and 2006. Whilst they concluded that delay to 
radical treatment was associated with a worse outcome, they did not quantify this effect. Given that 
the last ten years has seen a number of changes to the treatment of MIBC patients by RC (e.g. 
centralization of RC to larger hospitals, neoadjuvant chemotherapy (NAC), robotic cystectomy, pre-
habilitation), we aimed to re-assess this question by reviewing more recent studies, quantifying the 
effect of a delay on survival using meta-analyses and establishing a standardised definition of a delay 
in radical treatment.  
 
2.0 Evidence Acquisition 
2.1 Search strategy and inclusion criteria 
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The research question, search strategy, and inclusion and exclusion criteria were defined by 
a protocol (see Appendix). Studies were identified by conducting searches of Medline (PubMed) and 
Ovid Gateway (Embase and Ovid) using the search terms: “bladder” and/or “tumours” and/or 
“cancer”, “survival” or “death” and “delay” or “referral”. Initially, the titles of the studies were 
screened to identify the relevant studies. The abstracts and subsequently full texts were then 
carefully read to identify those which met the inclusion criteria. We used the following inclusion 
criteria: an RCT or observational study, an original article (no commentaries, author’s replies, 
reviews, supplements, editorials or systematic reviews), written in English, included patients who 
have undergone RC for bladder cancer, reported outcomes in the form of overall survival and/or BC 
specific survival and/or 5-year survival estimates, must not be looking at an alternative treatment 
regime to surgery and must include at least one category of delay between diagnosis of BC to 
definitive treatment with RC. There were no criteria of selection based on the date of publication as 
to include all results possible into the meta-analysis. Clinical characteristics, number of study 
participants, country of study and delay definitions were extracted from each study. The search was 
carried out in August 2019. Screening of titles, abstracts and full texts was carried out by BR and 
MVH. There were no disagreements between authors. BR extracted the data from the chosen 
articles.   
 
2.2 Meta-analyses 
Studies were deemed suitable for inclusion in the meta-analysis if they reported both HRs and 95% 
CIs for overall survival as an outcome.The studies were categorised based on the type of delay 
investigated (total delay from diagnosis of BC to RC,delay between TURBT and RC and delay between 
termination of NAC and RC) and each category was meta-analysed separately. Random-effects 
models were used whereby the presence of a delay was the exposure variable and overall survival 
was the outcome of interest (measured using the adjusted HRs from each study), for which pooled 
HRs were calculated. For each meta-analysis, sensitivity analyses were performed by removing each 
individual study, one at a time, to detect any changes in the overall result. I2 scores were also 
reported to define the severity of heterogeneity. 
 
2.3 Quality assessment of studies 
All included studies were classified as observational therefore the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) 22-item checklist was used asses the quality of the 
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articles (11). A risk of bias assessment was also carried out using the Risk Of Bias in Non-randomised 
Studies – of Interventions (ROBINS-I) tool (12). The review was also conducted in accordance with 
the PRISMA guidelines to enhance the quality of the results and was registered on PROSPERO 
(registration number: CRD42018118936).  
 
3.0 Evidence Synthesis 
Our search strategy identified 399 articles (Figure 1). From these, 38 duplicates were excluded and a 
further 324 texts were excluded based on the inclusion criteria outlined above following title and 
abstract review. The full texts of 37 articles were then read, of which 19 were deemed suitable for 
inclusion.  
 
All of the remaining 19 texts were observational studies published between 1991 and 2019. The 
sample sizes ranged from 10 to 2738, with a total of 17,532 patients who underwent RC in the 
studies. Eight of the studies were conducted in the USA, four in Canada, two in the UK, two in 
Germany and one in each of the Netherlands, Sweden and New Zealand.  
 
3.1 Quality of studies 
Assessment of each study using the STROBE checklist highlighted those studies of particularly high or 
poor quality (Supplementary Table 1). Most studies were of good quality according to the checklist; 
however, the studies by Munro et al (2010) and Kahokehr, Glasson and Studd (2016) appeared to 
satisfy the fewest checklist items and therefore were deemed to have a lower quality when 
compared to the other studies. The studies by Gulliford et al (1991), Williams et al (2017), Santos et 
al (2015), Mahmud et al (2006), Kulkarni et al (2009),Audenet et al (2019) and Boeri et al (2019) 
were considered to be of high quality. A risk of bias assessment revealed that all of the studies were 
considered to have either a low or moderate risk of bias (Supplementary Table 2) (12). The impact of 
this variation was assessed through our leave one out sensitivity analyses (see below). Furthermore, 
only 6 of the studies stated whether ethical approval or approval to use the respective databases 
was obtained.  
 
3.2 Delay and survival 
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The results from the 19 studies varied greatly, as did the methodology and therefore interpretation 
of the results. There was a variation in the type of delay investigated within the pathway from 
diagnosis of BC to RC (as shown in Tables 2 and 3). Ten of the studies evaluated the total delay 
between diagnosis of BC and RC of which one included patients who received NAC (13–22). Seven of 
the studies assessed the effect of the delay between TURBT and RC; all but one of these looked 
specifically at the most recent TURBT, whilst Jäger et al (2010) analysed a delay in RC in the context 
of NMIBC and used the first TURBT as the start date for analysis (23–29). Two of these studies 
carried out additional analyses for patients who received NAC. There were two studies which only 
investigated the delay between NAC and RC (30,31). 
 
3.3 Delay between diagnosis of BC and RC 
There was disparity in the number of days/months at which a significant association between delay 
and survival was identified (Tables 2 and 3). Several studies incorporated tumour stage into their 
analysis, and many concluded that this factor had a significant impact on the results. Overall, four of 
the studies found a significant association between delay from diagnosis to RC and survival (Tables 2 
and 3) (13,16,19,21).  
 
3.4 Delay between TURBT and RC  
Kulkarni et al (2009) used cubic spline regression analysis to recommend an ideal wait time of 40 
days. Audenet et al (2019) first looked at the time from TURBT and RC as a continuous variable and 
found no significant association with overall survival. They then looked at this time interval in deciles 
and concluded no significant cut-off point in predicting worse overall survival up to the ninth decile 
(222 days) (18). Overall, four of the studies found an association between the delay to RC after 
TURBT and survival (Tables 2 and 3) (25–28). 
 
3.5 Use of neoadjuvant chemotherapy 
Five studies included separate analyses for patients who received NAC to determine whether a delay 
in time after NAC to RC is associated with survival (18,28–31). Neither studies by Alva et al (2012) or 
Bruins et al (2016) found a significant association between a delay to RC after NAC and survival 
(29,30). Other studies included NAC patients in the overall analyses but in the case of Kahokehr, 
Glasson and Studd (2016), they looked at the time period between the last cycle of treatment and 
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surgery and its effect on survival. This study concluded a paucity of significance between survival and 
delay when also including patients who received NAC (24). Chu et al (2019) and Boeri et al (2019 
both investigated the time from the last documented infusion with NAC and RC. Both studies found 
that a longer delay between NAC and RC significantly increased risk of overall death (28,31). 
Audenet et al (2019) looked at the time from diagnosis to initiation of NAC and concluded that 
patients with a delay of 6 months or more had a significantly worse overall survival (18).  
 
3.6 Reasons for delays 
Several studies included reasons as to why treatment with RC was delayed. The studies by Lee et al 
(2006) and Alva et al (2012) suggested that scheduling was one of the main causes for delay in 
surgical treatment, with as many as 46% of the cohort in the study by Lee et al being affected by 
this. Other causes included seeking multiple medical opinions, social issues and misdiagnosis. Both 
Lee et al and Gore et al (2009) suggested that a reluctance to treat and patients’ comorbidities also 
contributed to delays, with two other studies also reaching the same conclusion. According to Gore 
et al, comorbidities affected the delay since patients had to wait to be transferred to centres better-
equipped to deal with the burden of care, as well as requiring more time for medical optimisation.  
 
Chu et al (2019) ran a separate logistic regression analysis to identify factors affecting whether the 
patients experienced a delay or not. They concluded that living in a high-poverty neighbourhood or 
rural area, and being transferred to another care provider between TURBT and RC were associated 
with increased RC delays. Conversely, no patient, provider or health system factors were found to be 
independently associated with RC delays in the NAC cohort (28). Boeri et al also looked into factors 
associated with a delay and found that patients with a higher CCI (≥1) were associated with a longer 
median time to cystectomy (31).  
 
3.7 Gender Disparities 
Most of the studies investigated gender in terms of the varying delays experienced by patients 
and/or how survival was affected by delay between genders. Fahmy et al (2008) additionally found a 
significant association between an increased median delay (defined as the period between visiting a 
family practitioner to seeing a urologist) in women when compared to men (21). They also 
concluded that men were more likely to experience a delay of less than 20 days than women for the 
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same time period. In contrast, Chu et al (2019) identified male gender as an independent 
characteristic associated with RC delays (28).  
 
3.8 Meta-analyses  
The delay definitions for each study are outlined in Figure 2 and these were considered as the 
exposure variables in the meta-analyses. When studying the delay between diagnosis of BC and RC, 
the meta-analysis revealed a pooled HR of 1.34 (95% CI: 1.18-1.53) for overall survival (Figure 3). 
Sensitivity analyses by the removal of individual studies did not identify any significant changes in 
the results. The I2 test was 0.0% suggesting a very low level of heterogeneity between the studies. 
For delay between TURBT and RC, the meta-analysis calculated a pooled HR of 1.18 (95% CI: 0.99-
1.41) for overall survival (Figure 3). The removal of individual studies in the sensitivity analyses did 
not significantly change the overall result for all studies except Kulkarni et al (2009). Removal of this 
study resulted in a pooled HR of 1.26 (95% CI: 1.06-1.51). The I2 test was 72.9%, indicating a 
relatively high level of heterogeneity between the studies. For a delay between NAC and RC, the 
meta-analysis calculated an HR of 1.04 (95% CI: 0.93-1.16) for overall survival (Figure 3). Sensitivity 
analyses by the removal of individual studies did not identify any significant changes in the 
results.The funnel plots for the meta-analyses appear to suggest a slight publication bias in the 
direction of worse survival associated with delay (Supplementary Figure 1).  
 
3.9 Discussion 
This is the first study to estimate the pooled effect on survival from a delay in RC using results from 
multiple studies. Our findings suggest that a longer period of time between diagnosing BC and 
undergoing RC negatively impacts the overall survival of patients and is influenced by many factors. 
This review also highlights that despite the 12-week EAU guideline, many centres do not adhere to 
this and/or choose to analyse their data using different cut-offs. We therefore need to work out a 
safe cut-off, and ensure there is consensus in how delay is defined. 
 
Whilst the pooled meta-analysis for a delay between TURBT and RC was not significant, removal of 
the study by Kulkarni et al (2009) resulted in a significant result. Interestingly Kulkarni et al treated 
delay as a continuous variable which may be a contributing factor as to why this result varied from 
the others.  
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The previous systematic review conducted by Fahmy and colleagues concluded that the majority of 
studies confirmed that delays were associated with worse outcomes (5). Similar to the current study, 
Fahmy and colleagues found that there was a variation in the type of delay investigated and the 
period of time used to define delay. A major advantage of the current study compared to the 
previous review is the inclusion of meta-analyses to quantify the impact that delays to RC may have 
on overall survival. Furthermore, most of the studies included were published after 2006, therefore 
incorporating data that were not available at the time of the previous review (5).   
 
Comorbidities, scheduling delays and reluctance to be treated were all suggested as substantial 
contributors to treatment delay (13,16,19,24). Of these three factors, scheduling delays should be 
both manageable and avoidable. However, the so called “distance bias effect”, suggesting improved 
survival for patients referred to a distant higher-volume hospital for RC (32), also generates 
prolonged treatment delay - “a volume delay paradox” that needs to be handled in clinical practice 
(33). Nevertheless, an awareness of this phenomenon could still motivate hospitals to have patients 
treated in a timely manner and subsequently improve outcomes. Comorbidities and reluctance to 
treat are much harder variables to manage; it is crucial that clinicians are aware of their impact on 
treatment delay and, hence, survival. Accessible patient information and signposting to peer support 
groups can help patients address their reluctance to be treated, by allowing them to receive 
encouragement and information directly from other people who have had an RC.  
 
Administering NAC to improve survival after RC also adds complexity to the scheduling process 
before RC, and delays to the start of such preoperative chemotherapy by more than 8 weeks has 
been associated with pathological upstaging (18). The studies included in this review found mixed 
results between a delay in RC and survival in patients who received NAC with the meta-analysis 
finding no significant association. It is known that NAC prior to RC significantly reduces patient 
mortality (34,35), however from the current data it is not possible to identify whether the lack of an 
effect of delay on mortality in those who received NAC is due to the potential beneficial effects of 
NAC. Furthermore, patients who receive NAC tend to be younger with fewer comorbidities and are 
therefore already at a survival advantage (36).  
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Most of the studies investigating disparities in delay time and/or survival amongst men and women 
did not find any significant association. This suggests that both males and females are equally as 
likely to experience delay and are both similarly affected by delays to RC: although delays in the 
referral of symptomatic female patients from primary care to secondary care may contribute to a 
stage migration at eventual diagnosis, there is no such disparity in secondary care (37).  
 
Some studies (e.g. Gulliford et al (1991), Munro et al (2010) (14,15)) did not limit their exposure to 
only include RC and additionally included radical radiotherapy and systemic chemotherapy as 
treatment options. Therefore, we could not be certain that the delays associated with the risk of 
survival were accurate for delay to RC and these studies were subsequently excluded from the meta-
analysis.  
 
Despite the 3-month guideline set by the EAU, it is clear from this review that not all centres are 
adhering to this guideline and many of the studies available use varied cut-off points for their 
analysis. There is also uncertainty as to the definition of the starting point for delay, e.g. at onset of 
symptoms, at diagnosis, at initial TURBT, or after termination of NAC. For example, the 40 days 
suggested by Kulkarni et al refers to the delay between TURBT and cystectomy in an era before NAC 
was widespread (27). However, the development of rapid access diagnostic pathways for patients 
with macroscopic haematuria strongly suggest the haematuria referral date as the starting point for 
delay, and facilitate national guideline recommendations on treatment delay (38). Across all 
malignancies, BC patients experience the longest delays from symptom onset to diagnosis (39) and it 
is therefore advisable to strive toward a short delay between haematuria clinic assessment and RC 
(especially when one considers the psychological effects of delaying RC) (40). Equally, one may also 
argue that the first TURBT date is a clear, measureable time point to start timing a delay from. 
However, the results from this study suggests that a longer delay from this time point may not 
impact delay significantly. Possible reasons for this may be the de-bulking of the tumour during the 
procedure or the variation in the cut-offs used to define delay.  
 
3.10 Strengths and Limitations 
Many of the studies included were large cohort studies could generally be considered to have high 
external validity. However, the data used for the study by Alva and colleagues were obtained from a 
single-centre and consequently, as stated by the authors, is limited in terms of generalisability.  
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Tumour stage was found to be a major influential factor for prognosis and was included in most 
study analyses. However, the study by Santos et al (2015) did not adjust for stage which is a major 
limitation of this study (19). Alternatively, patients with more advanced tumour stages might be 
prioritised in scheduling ahead of patients with less advanced asymptomatic tumours (37,41); thus, 
tumour stage might affect the exposure variable in cohort studies investigating treatment delays. 
Chu et al (2019) additionally identified positive lymph node status as a strong predictor of an 
increased mortality among patients who received NAC (28). Therefore, those studies which failed to 
report pathological N stage are limited.    
 
There were not enough studies acquired in this review to be able to perform subgroup analyses by N 
or T stage. As mentioned, these variables can have an impact on survival therefore this is a limitation 
to the current meta-analyses. Another limitation is the paucity of data for fundamental variables in 
some studies; for example, Nielsen et al (2007) did not collect information on pre-existing co-
morbidities, potentially major contributory factors to prolonged delays. The most prominent 
limitation in this review was the heterogeneity between the studies due to the variation in the 
definition of delay, as well as the demographic composition of the cohorts and the endpoints of 
interest. This made comparing these different studies challenging (as noted by Mahmud et al (25)). 
The heterogeneity of the studies is highlighted in the relatively large I2 scores reported for the meta-
analyses.  
 
 
3.11 Future research  
Results from these studies have shed light on the complexity of the relationship between RC delays 
and survival. We therefore recommend that future studies consider this complexity when planning 
data capture. In the setting of the guideline recommended treatment of NAC and RC, we 
recommend these definitions for periods of delay to be used by future studies: 
• Symptom onset to primary care referral for urologic assessment; 
• Referral for urologic assessment to actual urologic assessment; 
• Initial urologic assessment to TURBT; 
• TURBT to commencement of NAC; 
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• Commencement of NAC to completion of NAC; 
• Completion of NAC to RC. 
Not all studies will be established to capture all time points, but the relevant components thereof 
are to be recommended. Furthermore, awareness of all of the components of total delay may 
highlight individual elements where pathways can be improved and/or optimised. 
 
4.0 Conclusions  
This systematic review has updated the data and knowledge regarding delays to RC and patient 
survival whilst the addition of the meta-analysis is the first time this pooled effect has been 
quantified. The BC diagnostic and treatment pathway is complex, involving generally elderly patients 
with multiple comorbidities; hence, some delays may be unavoidable. However, there still remains a 
lack of consensus as to what period of delay is acceptable before negatively impacting survival hence 
more work is needed to answer what has recently been identified as one of the top ten unanswered 
questions in BC. Notwithstanding, we have demonstrated that a longer delay from BC diagnosis to 
RC is associated with significantly worse survival. This current review has also highlighted the lack of 
standardisation as to how delays are defined and therefore using more fixed, measurable time 
points is of interest to future studies. In conclusion, bladder cancer patients who require RC should 
be treated without delay so as to maximise survival. Several factors impact delay, such as other 
medical conditions and scheduling, and these must be monitored by medical practitioners in order 
to minimise unnecessary delays and to maximise survival.   
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Tables and Figures 
Figure 1. PRISMA Flow diagram for selection of studies in systematic review and meta-analysis 
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Table 2.  
Study ID Reference Authors and 
year of 
publication 
Delay definition Delay cut-off Results 
Median delay Conclusions 
Delay between diagnosis of BC and RC 
1 (13) Lee et al, 
2006 
Diagnosis of BC to 
RC 
93 days 61 days Those delayed longer than 93 days were at a 96% 
increased risk of death from any cause and 112% 
increased risk of death from BC compared to those 
with a cystectomy delay of 93 days or less. 
2 (14) Gulliford et 
al, 1991 
Referral to 1st 
treatment 
84 days N/A No change in survival when first treatment was 
delayed. 
3 (22) Williams et al, 
2017 
Diagnosis of BC to 
RC 
84 days N/A No change in overall or cancer-specific survivals when 
RC was delayed. 
4 (15) Munro et al, 
2010 
1st clinic to 
radiotherapy or RC 
84 days N/A No change in survival when radiotherapy or RC was 
delayed. 
5 (16) Gore et al, 
2009 
Diagnosis of BC to 
RC 
28-56, 56-84, 
84-168 & ≥168 
days 
N/A A delay of more than 12 weeks between diagnosis and 
RC was associated with a 201% increased risk of all 
cause and disease-specific mortality (p=0.003). 
 8 (17) Liedberg, 
Anderson and 
Månsson, 
2005 
Diagnosis of BC to 
RC 
60 days 49 days No change in disease specific survival when there was 
a delay between diagnosis and RC. 
Delay between TURBT and RC 
6 (23) Nielsen et al, 
2007 
TURBT to RC  90 days 55 days No change in survival when there was a delay between 
the most recent TURBT and RC. 
Studies which were also inclusive of NAC patients 
15 
 
7 (24) Kahokehr, 
Glasson and 
Studd, 2016 
TURBT to RC  31 days Mean = 62 days No change in survival when there was a delay between 
TURBT and RC. 
9 (18) Audenet et al, 
2019 
Diagnosis of BC to 
RC 
From diagnosis 
to initiation of 
NAC: 56 days 
From diagnosis 
to RC: 183 days 
From diagnosis to 
initiation of NAC: 
39 days 
From initiation of 
NAC to RC: 112 
days  
No significant change in overall survival when there 
was an increase in time from diagnosis to surgery with 
or without the use of NAC. An increase in time from 
diagnosis to chemotherapy (≥56 days) was associated 
with an increased risk of pathological upstaging 
(OR=1.27, 95% CI: 1.02-1.59).  
Table 2. Delay definitions and summary of results for studies included in systematic review only. TURBT – transurethral resection of the bladder tumour, BC – 
bladder cancer, RC – radical cystectomy, NAC – neoadjuvant chemotherapy 
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Table 3.  
Study ID Reference Authors and 
year of 
publication 
Delay definition Delay cut-off Results 
Median delay Conclusions 
Delay between diagnosis of BC and RC 
12 (19) Santos et al, 
2015 
Diagnosis of BC to 
RC (including 
referral delay) 
Direct/indirect 
referral 
30 days Patients indirectly referred to a urologist after a first 
GP visit experienced a 29% increased risk of mortality 
compared to those directly referred (95% CI: 1.10-
1.52). 
13 (20) May et al, 
2004 
Diagnosis of BC to 
RC 
90 days 55 days No change in overall survival when RC was delayed, 
though this relationship was borderline significant 
(HR=1.62, 95% CI: 0.99-2.66). 
14 (21) Fahmy et al, 
2008 
Diagnosis of BC to 
RC 
≤24, 24-84, ≥85 
days 
93 days A delay of less than 25 or more than 84 days between 
visiting the family physician and RC was associated 
with a 230% and 40% increased risk of death from any 
cause respectively (95% CI: 1.4-3.9 and 1.1-1.8 
respectively). 
Delay between TURBT and RC 
15 (25) Mahmud et 
al, 2006 
TURBT to RC  84 days 33 days A delay of more than 12 weeks between the most 
recent TURBT and RC is associated with a 20% 
increased risk of dying from any cause (95% CI: 1.00-
1.50). 
16 (26) Jäger et al, 
2010 
TURBT to RC  120 days 122 days A delay of more than 120 days between the first 
TURBT and RC was associated with a significantly 
worse 5-year cancer-specific survival compared to 
those with a delay of less than 120 days (77% vs 86% 
respectively). 
17 (27) Kulkarni et al, 
2009 
TURBT to RC  90 days 50 days A delay of more than 90 days between TURBT and RC 
was associated with an increased risk of death from all 
causes compared to those with a delay of 90 days or 
less (HR=1.001, 95% CI:1.000-1.002). This represents 
17 
 
an increased risk of death for each day a patient waits 
for an RC. 
18 (28) Chu et al, 
2019 
TURBT to RC,  From TURBT to 
RC: 84 days 
 
N/A Overall survival was significantly reduced in patients 
who did not receive NAC and were aged less than 80 
years old (HR: 1.39, p<0.05).  
 
11 (29) Bruins et al, 
2016 
TURBT to RC 60 days No NAC: 50 days 
NAC: 133 days 
No change in survival when there was a delay between 
diagnosis of BC and RC.  
Delay between NAC and RC 
10 (30) Alva et al, 
2012 
NAC to RC 28-84 days From initiation of 
NAC: 117 days 
From termination 
of NAC: 49 days 
No change in survival when there was a delay between 
the termination of NAC treatment and RC or between 
initiation of NAC to RC. 
19 (31) Boeri et al, 
2019 
NAC to RC 70 days 53 days A time to cystectomy (TTC) of more than 10 weeks was 
associated with an adverse overall and bladder cancer-
specific survival  
18 (28) Chu et al, 
2019 
TURBT to RC and 
NAC to RC 
From 
completion of 
NAC to RC: 77 
days 
N/A Patients who received NAC and whose RC was delayed 
suffered significantly higher mortality over time. 
Table 3. Delay definitions and summary of results for studies included in the meta-analyses. The cut-off points for each study is the one from which the HRs 
and 95% CIs were taken from for the meta-analyses. TURBT – transurethral resection of the bladder tumour, BC – bladder cancer, RC – radical cystectomy, 
NAC – neoadjuvant chemotherapy  
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Figure 2. Delay definitions for total delay (diagnosis of BC to RC) and delay between 
TURBT and RC 
 
(a) Number of days used by each study to define a total delay in patients receiving treatment by 
radical cystectomy. Santos et al (2008) is not included as the delay was defined as ‘direct’ or ‘indirect’ 
referral and was therefore not able to be depicted on the diagram. (b) Number of days used by each 
19 
 
study to define a delay between TURBT and RC. Kulkarni et al (2009) is not included in the diagram as 
delay was treated as a continuous variable. BC – bladder cancer, RC – radical cystectomy, TURBT – 
transurethral resection of bladder tumour 
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Figure 3. Forest Plots  
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(a) Forest plot for total delay between diagnosis of bladder cancer and radical cystectomy. (b) Forest 
plot for delay from TURBT to RC. TURBT – transurethral resection of the bladder tumour. (c) Forest 
plot for delay between termination of NAC and radical cystectomy. RC – radical cystectomy.  
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Supplementary Tables and Figures 
Supplementary Figure 1.  Funnel plots for studies included in meta-analyses 
23 
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Funnel plot for studies included in meta-analyses. (a) From diagnosis of BC to RC, (b) TURBT to RC, (c) NAC to RC.  
RC – radical cystectomy, BC – bladder cancer, TURBT – transurethral resection of the bladder tumour, NAC – neoadjuvant chemotherapy  
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Supplementary Table 1.  
Item Item 
No. 
Recommendation Study ID 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
 Title and 
abstract 
1 (a) Indicate the study’s 
design with a 
commonly used term 
in the title or the 
abstract 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
(b) Provide in the 
abstract an informative 
and balanced summary 
of what was done and 
what was found 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Introduction                                           
Background/ 
rationale 
2 Explain the scientific 
background and 
rationale for the 
investigation being 
reported 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Objectives 3 State specific 
objectives, including 
any prespecified 
hypotheses 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Methods                                           
Study design 4 Present key elements 
of study design early in 
the paper 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Setting 5 Describe the setting, 
locations, and relevant 
dates, including 
periods of recruitment, 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
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exposure, follow-up, 
and data collection 
Participants 6 (a) Give the eligibility 
criteria, and the 
sources and methods 
of selection of 
participants. Describe 
methods of follow-up 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
(b) For matched 
studies, give matching 
criteria and number of 
exposed and 
unexposed 
N/A N/A Y N/A N/A N/A N/A N/A N/A Y N/A N/A N/A N/A N/A N/A N/A N/A - 
Variables 7 Clearly define all 
outcomes, exposures, 
predictors, potential 
confounders, and 
effect modifiers. Give 
diagnostic criteria, if 
applicable 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Data sources/ 
measurement 
8* For each variable of 
interest, give sources 
of data and details of 
methods of 
assessment 
(measurement). 
Describe comparability 
of assessment 
methods if there is 
more than one group 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y   Y Y 
Bias 9 Describe any efforts to 
address potential 
sources of bias 
N Y N N Y N N Y Y N N N/A N Y Y N Y Y N 
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Study size 10 Explain how the study 
size was arrived at Y Y Y Y Y Y N Y Y N Y Y Y Y Y Y Y Y Y 
Quantitative 
variables 
11 Explain how 
quantitative variables 
were handled in the 
analyses. If applicable, 
describe which 
groupings were chosen 
and why 
Y Y Y N Y N N N Y N N Y N/A N/A Y N N/A Y Y 
Statistical 
methods 
12 (a) Describe all 
statistical methods, 
including those used to 
control for 
confounding 
Y Y Y N Y Y N Y Y Y Y Y Y Y Y Y Y Y Y 
(b) Describe any 
methods used to 
examine subgroups 
and interactions 
Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
(c) Explain how missing 
data were addressed 
Y N Y N N N N N N N N N N N N N Y N N 
(d) If applicable, 
explain how loss to 
follow-up was 
addressed 
N N N N N N N N Y Y N N N Y N/A N Y N Y 
(e) Describe any 
sensitivity analyses 
N N N Y Y N N Y N Y Y Y N N Y N Y Y N 
Results     
                                      
Participants 13* (a) Report numbers of 
individuals at each 
stage of study—e.g. 
numbers potentially 
eligible, examined for 
eligibility, confirmed 
eligible, included in the 
study, completing 
Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y 
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follow-up, and 
analysed 
(b) Give reasons for 
non-participation at 
each stage 
N N N N N N Y Y Y N Y Y N Y N N N Y N 
(c) Consider use of a 
flow diagram 
N N N N N N N N Y N N Y N N N N N N N 
Descriptive data 14* (a) Give characteristics 
of study participants 
(e.g. demographic, 
clinical, social) and 
information on 
exposures and 
potential confounders 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y 
(b) Indicate number of 
participants with 
missing data for each 
variable of interest 
N Y Y N N N N Y N N N Y N N N N N N Y 
(c) Summarise follow-
up time (e.g., average 
and total amount) 
N N N N N Y N N Y Y Y Y Y N N Y Y N Y 
Outcome data 15* Report numbers of 
outcome events or 
summary measures 
over time 
Y Y Y N N N N N N N N Y N N Y N Y N Y 
29 
 
Main results 16 (a) Give unadjusted 
estimates and, if 
applicable, 
confounder-adjusted 
estimates and their 
precision (e.g., 95% 
confidence interval). 
Make clear which 
confounders were 
adjusted for and why 
they were included 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
(b) Report category 
boundaries when 
continuous variables 
were categorized 
Y Y Y N/A Y N N N/A Y Y N/A Y Y N Y Y N Y Y 
(c) If relevant, consider 
translating estimates 
of relative risk into 
absolute risk for a 
meaningful time 
period 
N/A N/A N/A Y N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A - 
Other analyses 17 Report other analyses 
done—e.g. analyses of 
subgroups and 
interactions, and 
sensitivity analyses 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Discussion     
                
  
                
    
Key results 18 Summarise key results 
with reference to study 
objectives 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Limitations 19 Discuss limitations of 
the study, taking into 
account sources of 
potential bias or 
imprecision. Discuss 
Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y 
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both direction and 
magnitude of any 
potential bias 
Interpretation 20 Give a cautious overall 
interpretation of 
results considering 
objectives, limitations, 
multiplicity of analyses, 
results from similar 
studies, and other 
relevant evidence 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Generalisability 21 Discuss the 
generalisability 
(external validity) of 
the study results 
Y Y Y N Y N Y Y N Y Y Y N Y Y N Y N Y 
Other 
information 
    
                
  
                
    
Funding 22 Give the source of 
funding and the role of 
the funders for the 
present study and, if 
applicable, for the 
original study on which 
the present article is 
based 
N Y Y N Y N N N N Y Y Y N N Y N N Y Y 
Total Score 24 26 26 19 25 20 19 24 26 25 24 29 20 23 26 20 25 24 27 
Assessment of studies according to STROBE checklist. Y=Yes, N=No. Each yes was given a score of 1 and was totalled in the final row.  
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Supplementary Table 2.  
Signalling questions Study ID  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1.1 Is there potential 
for confounding of 
the effect of 
intervention in this 
study? 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
If N/PN to 1.1: the 
study can be 
considered to be at 
low risk of bias due 
to confounding and 
no further signalling 
questions need be 
considered 
- - - - - - - - - - - - - - - - - - - 
If Y/PY to 1.1: 
determine whether 
there is a need to 
assess time-varying 
confounding: 
- - - - - - - - - - - - - - - - - - - 
1.2. Was the analysis 
based on splitting 
participants’ follow 
up time according to 
intervention 
received? 
PN N N N N N PN PN PN N PN PN N N PN PN PN N N 
If N/PN, answer 
questions relating to 
baseline 
confounding (1.4 to 
- - - - - - - - - - - - - - - - - - - 
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1.6) If Y/PY, proceed 
to question 1.3. 
1.3. Were 
intervention 
discontinuations or 
switches likely to be 
related to factors 
that are prognostic 
for the outcome? 
- - - - - - - - - - - - - - - - - - - 
If N/PN, answer 
questions relating to 
baseline 
confounding (1.4 to 
1.6) If Y/PY, answer 
questions relating to 
both baseline and 
time-varying 
confounding (1.7 and 
1.8) 
- - - - - - - - - - - - - - - - - - - 
Questions relating 
to baseline 
confounding only 
 - - - - - - - - - - - - - - - - - - 
1.4. Did the authors 
use an appropriate 
analysis method that 
controlled for all the 
important 
confounding 
domains? 
Y Y Y PN PN PN PN Y PN PN PN N N PN N PN Y Y Y 
1.5. If Y/PY to 1.4: 
Were confounding 
domains that were 
controlled for 
Y Y Y - Y - - - - PY - - - PY - - Y Y Y 
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measured validly and 
reliably by the 
variables available in 
this study? 
1.6. Did the authors 
control for any post-
intervention 
variables that could 
have been affected 
by the intervention? 
PN N N - N N N N N N N N N N N N N N N 
 Questions relating 
to baseline and 
time-varying 
confounding 
- - - - - - - - - - - - - - - - -   
1.7. Did the authors 
use an appropriate 
analysis method that 
adjusted for all the 
important 
confounding 
domains and for 
time-varying 
confounding? 
- - - - - - - - - - - - - - - - - - - 
1.8. If Y/PY to 1.7: 
Were confounding 
domains that were 
adjusted for 
measured validly and 
reliably by the 
variables available in 
this study? 
- - - - - - - - - - - - - - - - - - - 
Risk of bias 
judgement 
Low Low Low Mod Mod Mod Mod Low Mod Mod Mod Mod Mod Mod Mod Mod Low Low Low 
34 
 
2.1. Was selection of 
participants into the 
study (or into the 
analysis) based on 
participant 
characteristics 
observed after the 
start of 
intervention? 
N N N N N N N N N N N N N N N N N N N 
If N/PN to 2.1: go to 
2.4 
- - - - - - - - - - - - - - - - - - - 
2.2. If Y/PY to 2.1: 
Were the post-
intervention 
variables that 
influenced selection 
likely to be 
associated with 
intervention? 
- - - - - - - - - - - - - - - - - - - 
 2.3 If Y/PY to 2.2:  
Were the post-
intervention 
variables that 
influenced selection 
likely to be 
influenced by the 
outcome or a cause 
of the outcome? 
- - - - - - - - - - - - - - - - - - - 
2.4. Do start of 
follow-up and start 
of intervention 
coincide for most 
participants? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
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2.5. If Y/PY to 2.2 
and 2.3, or N/PN to 
2.4: Were 
adjustment 
techniques used that 
are likely to correct 
for the presence of 
selection biases? 
- - - - - - - - - - - - - - - - - - - 
Risk of bias 
judgement 
Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low 
3.1 Were 
intervention groups 
clearly defined? 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
3.2 Was the 
information used to 
define intervention 
groups recorded at 
the start of the 
intervention? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
3.3 Could 
classification of 
intervention status 
have been affected 
by knowledge of the 
outcome or risk of 
the outcome? 
PY PY PY PY PY PY PY PY PY PY PY PY PY PY PY PY PY PY PY 
Risk of bias 
judgement 
Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low 
If your aim for this 
study is to assess 
the effect of 
assignment to 
intervention, 
- - - - - - - - - - - - - - - - - - - 
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answer questions 
4.1 and 4.2 
4.1. Were there 
deviations from the 
intended 
intervention beyond 
what would be 
expected in usual 
practice? 
PN PN PN PN PN PN PN PN PN PN PN PN PN PN PN PN PN N N 
4.2. If Y/PY to 4.1: 
Were these 
deviations from 
intended 
intervention 
unbalanced between 
groups and likely to 
have affected the 
outcome? 
- - - - - - - - - - - - - - - - - - - 
If your aim for this 
study is to assess 
the effect of starting 
and adhering to 
intervention, 
answer questions 
4.3 to 4.6 
- - - - - - - - - - - - - - - - - - - 
4.3. Were important 
co-interventions 
balanced across 
intervention groups? 
- - - - - - - - - - - - - - - - - - - 
4.4. Was the 
intervention 
implemented 
- - - - - - - - - - - - - - - - - - - 
37 
 
successfully for most 
participants? 
4.5. Did study 
participants adhere 
to the assigned 
intervention 
regimen? 
- - - - - - - - - - - - - - - - - - - 
4.6. If N/PN to 4.3, 
4.4 or 4.5: Was an 
appropriate analysis 
used to estimate the 
effect of starting and 
adhering to the 
intervention? 
- - - - - - - - - - - - - - - - - - - 
Risk of bias 
judgement 
Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low 
5.1 Were outcome 
data available for all, 
or nearly all, 
participants? 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
5.2 Were 
participants 
excluded due to 
missing data on 
intervention status? 
N NI N Y N N N N Y N N N N N N N Y Y N 
5.3 Were 
participants 
excluded due to 
missing data on 
other variables 
needed for the 
analysis? 
N Y PN PN N N N N Y N N Y N N PN N Y N N 
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5.4 If PN/N to 5.1, or 
Y/PY to 5.2 or 5.3: 
Are the proportion 
of participants and 
reasons for missing 
data similar across 
interventions? 
- Y - Y - - - - PY - - PY - - - - PY N/A N/A 
5.5 If PN/N to 5.1, or 
Y/PY to 5.2 or 5.3: Is 
there evidence that 
results were robust 
to the presence of 
missing data? 
- Y - Y - - - - PY - - PY - - - - Y Y N/A 
Risk of bias 
judgement 
Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low 
6.1 Could the 
outcome measure 
have been 
influenced by 
knowledge of the 
intervention 
received? 
N N N N N N N N N N N N N N N N N N N 
6.2 Were outcome 
assessors aware of 
the intervention 
received by study 
participants? 
N/A N/A N/A N N N N N N N N N N N N N N N N 
6.3 Were the 
methods of outcome 
assessment 
comparable across 
intervention groups? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
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6.4 Were any 
systematic errors in 
measurement of the 
outcome related to 
intervention 
received? 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Risk of bias 
judgement 
Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low N/A N/A 
Is the reported effect 
estimate likely to be 
selected, on the 
basis of the results, 
from...   
- - - - - - - - - - - - - - - - - - - 
7.1. ... multiple 
outcome 
measurements 
within the outcome 
domain? 
N N PN N N N N N N N N N N N N N N N N 
7.2 ... multiple 
analyses of the 
intervention-
outcome 
relationship? 
N N PN N N N N N N N N PN N N N N N N N 
7.3 ... different 
subgroups? 
N N PN N N N N N N N N PY N N N N N N N 
Risk of bias 
judgement 
Low Low Low Low Low Low Low Low Low Low Low Mod Low Low Low Low Low Low Low 
Overall Risk of bias 
judgement 
Low Low Low Mod Mod Mod Mod Low Mod Mod Mod Mod Mod Mod Mod Mod Low Low Low 
Risk of bias for all studies using the Risk of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool. N= no; PN= probably no; Y = yes; PY= 
probably yes ; N/A= not applicable. Mod= Moderate risk of bias 
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Appendix 
Protocol for systematic review 
1) Formulate review question 
PICOS Question formulation 
Population – Bladder cancer patients 
Intervention/Exposure – Delayed cystectomy  
Comparison – Non-delayed cystectomy 
Outcomes – survival  
Study designs – RCTs and observational studies, written in English only 
In patients with bladder cancer, does having a longer delay between diagnosis and cystectomy have 
an effect on survival when compared to those who have a shorter time between diagnosis and 
cystectomy.  
2) Define inclusion and exclusion criteria 
Search criteria 
("urinary bladder"[MeSH Terms] OR ("urinary"[All Fields] AND "bladder"[All Fields]) OR "urinary 
bladder"[All Fields] OR "bladder"[All Fields]) AND (("tumours"[All Fields] OR "neoplasms"[MeSH 
Terms] OR "neoplasms"[All Fields] OR "tumors"[All Fields]) OR ("neoplasms"[MeSH Terms] OR 
"neoplasms"[All Fields] OR "cancer"[All Fields])) AND (("mortality"[Subheading] OR "mortality"[All 
Fields] OR "survival"[All Fields] OR "survival"[MeSH Terms]) OR ("death"[MeSH Terms] OR 
"death"[All Fields])) AND (delay[All Fields] OR ("referral and consultation"[MeSH Terms] OR 
("referral"[All Fields] AND "consultation"[All Fields]) OR "referral and consultation"[All Fields] OR 
"referral"[All Fields]))  
Inclusion criteria 
• RCT or observational study, original article 
• Must include patients who have undergone RC 
• All patients are bladder cancer patients 
• Must include at least one category of delay between diagnosis of BC to definitive treatment 
with RC  
• Report of any overall survival and/or bladder-cancer specific survival and/or 5-year survival 
estimates  
Exclusion criteria 
• No mention of cystectomy 
• No mention of time between diagnosis and surgical intervention 
• Commentaries, Author’s replies, reviews, supplements, editorials, systematic reviews 
• Specific to another tumour type 
• Treatment not specific to surgery e.g. chemotherapy instillations 
• No outcome of survival 
 
41 
 
Databases to be searched: 
1. Medline (PubMed) 
2. Ovid Gateway (Embase and Ovid) 
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Legends: 
Figure 1. PRISMA Flow diagram for selection of studies in systematic review and meta-analysis 
 
Table 1.  
Descriptives of the studies included in the systematic review *Included in meta-analysis for total 
delay between diagnosis of bladder cancer to RC. **Included in meta-analysis for delay between 
TURBT to RC. ***Included in meta-analysis for delay between NAC and RC. cT/cN = clinical T/N stage  
 
Table 2. 
Delay definitions and summary of results. The cut-off points for each study is the one from which the 
HRs and 95% CIs were taken from for the meta-analyses. TURBT – transurethral resection of the 
bladder tumour, BC – bladder cancer, RC – radical cystectomy, NAC – neoadjuvant chemotherapy  
 
Table 3.  
Delay definitions and summary of results for studies included in the meta-analyses. The cut-off points 
for each study is the one from which the HRs and 95% CIs were taken from for the meta-analyses. 
TURBT – transurethral resection of the bladder tumour, BC – bladder cancer, RC – radical cystectomy, 
NAC – neoadjuvant chemotherapy  
 
Figure 2. Delay definitions for total delay (diagnosis of BC to RC) and delay between TURBT 
and RC  
(a) Number of days used by each study to define a total delay in patients receiving treatment by 
radical cystectomy. Santos et al (2008) is not included as the delay was defined as ‘direct’ or ‘indirect’ 
referral and was therefore not able to be depicted on the diagram. (b) Number of days used by each 
study to define a delay between TURBT and RC. Kulkarni et al (2009) is not included in the diagram as 
delay was treated as a continuous variable. BC – bladder cancer, RC – radical cystectomy, TURBT – 
transurethral resection of bladder tumour 
 
Figure 3. Forest Plots 
(a) Forest plot for total delay between diagnosis of bladder cancer and radical cystectomy. (b) Forest 
plot for delay from TURBT to RC. TURBT – transurethral resection of the bladder tumour. RC – radical 
cystectomy 
 
Supplementary Tables and Figures 
Supplementary Figure 1.  Funnel plots for studies included in meta-analyses 
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Funnel plot for studies included in meta-analyses. (a) From diagnosis of BC to RC, (b) TURBT to RC, (c) 
NAC to RC.  
RC – radical cystectomy, BC – bladder cancer, TURBT – transurethral resection of the bladder tumour, 
NAC – neoadjuvant chemotherapy  
 
Supplementary Table 1.  
Assessment of studies according to STROBE checklist. Y=Yes, N=No. Each yes was given a score of 1 
and was totalled in the final row.  
 
Supplementary Table 2.  
Risk of bias for all studies using the Risk of Bias In Non-randomised Studies - of Interventions 
(ROBINS-I) tool. N= no; PN= probably no; Y = yes; PY= probably yes ; N/A= not applicable. Mod= 
Moderate risk of bias 
 
